Compare Brown-Forman Corporation Class B (BF.B) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brown-Forman Corporation Class B vs Ginkgo Bioworks Holdings Inc — how do they compare? Brown-Forman Corporation Class B trades at $28.01, while Ginkgo Bioworks Holdings Inc trades at $7.28 (market cap $505.73M). The key difference: Brown-Forman Corporation Class B is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BF.B | DNA | |
|---|---|---|
Sector | Consumer Staples | Health |
52-Week High | $31.26 | $16.14 |
52-Week Low | $22.80 | $5.48 |
Market Cap | — | $505.73M |
Enterprise Value | — | $607.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BF.B trades at $27.92, down 0.96% with mixed technical signals showing bullish moving averages but neutral oscillators. The stock has demonstrated earnings momentum with three consecutive quarterly beats, though analyst coverage remains divided with a 25% buy rating. Recent price action shows consolidation around the $28 pivot point level.
The outlook remains cautiously optimistic given strong recent earnings performance, though limited analyst coverage and divided sentiment suggest moderate risk. Upside potential exists if earnings momentum continues, while downside risks include market volatility and potential execution challenges in maintaining growth trajectory.
Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.
The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
